
Shuichi Hironaka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2257472/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 1224-1235.	5.1	1,932
2	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2018, 392, 123-133.	6.3	984
3	Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncology, The, 2017, 18, 631-639.	5.1	324
4	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 420-435.	5.1	191
5	Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 277-287.	3.7	141
6	Phase II Study of Concurrent Chemoradiotherapy at the Dose of 50.4 Gy with Elective Nodal Irradiation for Stage II-III Esophageal Carcinoma. Japanese Journal of Clinical Oncology, 2013, 43, 608-615.	0.6	78
7	Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer, 2016, 19, 927-938.	2.7	67
8	A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. European Journal of Cancer, 2018, 91, 86-91.	1.3	48
9	Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer. Clinical Cancer Research, 2021, 27, 1029-1036.	3.2	46
10	Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Molecular Cancer Therapeutics, 2017, 16, 2215-2222.	1.9	41
11	Antiâ€angiogenic therapies for gastric cancer. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 208-217.	0.7	31
12	Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study. Neoplasia, 2018, 20, 1219-1226.	2.3	21
13	Longâ€ŧerm efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. Cancer Science, 2020, 111, 1676-1684.	1.7	21
14	Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07). Esophagus, 2021, 18, 835-843.	1.0	15
15	A single-arm confirmatory study of definitive chemoradiotherapy (dCRT) including salvage treatment in patients (pts) with clinical (c) stage II/III esophageal carcinoma (EC) (JCOG0909) Journal of Clinical Oncology, 2018, 36, 4051-4051.	0.8	15
16	Sex differences in the safety of Sâ€1 plus oxaliplatin and Sâ€1 plus cisplatin for patients with metastatic gastric cancer. Cancer Science, 2019, 110, 2875-2883.	1.7	13
17	Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study. Advances in Therapy, 2022, 39, 296-313.	1.3	13
18	Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2â€positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 5-13.	0.7	12

Shuichi Hironaka

#	Article	IF	CITATIONS
19	An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT,) Tj ETQq1 1 0.	78147314 rg	gBT‡Overloc
20	The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909. Esophagus, 2020, 17, 417-424.	1.0	8
21	Phase I Study of Docetaxel, Cisplatin and S-1 in Patients with Advanced Gastric Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 1014-1020.	0.6	4
22	Influence of preoperative chemotherapy-induced leukopenia on survival in patients with esophageal squamous cell carcinoma: exploratory analysis of JCOG9907. Esophagus, 2021, 18, 41-48.	1.0	4
23	Prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502â€A1. Cancer Science, 2022, 113, 1018-1027.	1.7	4
24	Factors associated with treatment duration from start of second-line ramucirumab plus paclitaxel or nab-PTX for advanced gastric cancer: real-world evidence from Japanese Claim Database Journal of Clinical Oncology, 2021, 39, 177-177.	0.8	1
25	Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial. Clinical Drug Investigation, 2021, 41, 53-64.	1.1	1
26	Association of renal function with the safety and efficacy of cisplatin plus S-1 therapy and docetaxel plus cisplatin plus S-1 therapy in patients with advanced gastric cancer: an exploratory analysis of JCOG1013. Japanese Journal of Clinical Oncology, 2022, 52, 14-23.	0.6	0
27	Phase II trial of adjuvant mFOLFOX6 after metastasectomy for pulmonary metastasis of colorectal cancer: WJOG5810G Journal of Clinical Oncology, 2020, 38, 4097-4097.	0.8	ο